BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  MacroGenic Scores $900M Checkpoint PD-1 R&D Deal With Incyte

  Incyte picked up MGA012 and the exclusive rights to develop the drug worldwide.

  October 25, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Ambu Scoops Up Invendo Medical in EUR 225M Deal

  Danish company Ambu plopped down $265M to acquire Germany-based Invendo Medical, a privately-held medtech company that develops single-use high definition endoscopy products.

  October 25, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  BioMidwest

  3 Biotechs Investors Should Put on Their Watchlist

  Three companies remain favorites, and all are rated Buy at Jefferies.

  October 25, 2017

   · 

  1 min read
• 

  Genetown

  This Massachusetts Marijuana Biotech is Betting the Farm on One Single Drug

  Corbus’ stock popped on the release of topline results from a midstage study involving its lead (and only) clinical drug, anabasum.

  October 25, 2017

   · 

  1 min read
• Biotech Bay

  Sunesis Announces Pricing of $20M Offering of Securities

  These offerings are expected to close on or about October 27, 2017, subject to customary closing conditions.

  October 25, 2017

   · 

  4 min read
• Business

  Natus Medical Announces Third Quarter 2017 Financial Results

  The company reported record third quarter 2017 revenue of $122.6 million

  October 25, 2017

   · 

  16 min read
• 

  Business

  The Medicines Company Slashes Hundreds of Jobs in Restructuring

  In addition to the layoffs, the company is also looking to divest its Infectious Disease Business.

  October 25, 2017

   · 

  2 min read

   · 

  Mark Terry
• Drug Development

  Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting

  Aldeyra Therapeutics presented novel data at the American Society of Human Genetics 2017 Annual Meeting demonstrating that ADX-102 reduced levels of gamma-hydroxybutyrate (GHB) and gamma-aminobutyrate (GABA) in a knockout mouse model of Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency.

  October 25, 2017

   · 

  6 min read
• 

  Deals

  VEXIM Acquired by Stryker in EUR 183M Deal

  Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures.

  October 25, 2017

   · 

  2 min read

   · 

  Alex Keown
• FDA

  China Approves Tianjin CanSino’s Ebola Vaccine

  Tianjin CanSino Biologics announced CFDA approval of its Ebola virus vaccine for China.

  October 25, 2017

   · 

  1 min read